---
document_datetime: 2023-09-21 21:55:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/inbrija-epar-all-authorised-presentations_en.pdf
document_name: inbrija-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8806744
conversion_datetime: 2025-12-26 17:40:46.067398
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form             | Route of Administration   | Immediate Packaging   | Pack size                               |
|------------------|-------------------|------------|---------------------------------|---------------------------|-----------------------|-----------------------------------------|
| EU/1/19/1390/001 | Inbrija           | 33 mg      | Inhalation powder, hard capsule | Inhalation use            | blister (alu/PVC/alu) | 60 x 1 capsules (unit dose) + 1 inhaler |
| EU/1/19/1390/002 | Inbrija           | 33 mg      | Inhalation powder, hard capsule | Inhalation use            | blister (alu/PVC/alu) | 92 x 1 capsules (unit dose) + 1 inhaler |
| EU/1/19/1390/003 | Inbrija           | 33 mg      | Inhalation powder, hard capsule | Inhalation use            | blister (alu/PVC/alu) | 16 x 1 capsules (unit dose) + 1 inhaler |
| EU/1/19/1390/004 | Inbrija           | 33 mg      | Inhalation powder, hard capsule | Inhalation use            | blister (alu/PVC/alu) | 32 x 1 capsules (unit dose) + 1 inhaler |